Healthcaremedical - Crivva

The growing demand for innovative tissue engineering solutions for the treatment of chronic diseases and for repair and regeneration of tissues and technological developments such as 3D bioprinting is promoting the growth of the tissue engineering market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34135173

Based on product type, the tissue engineering market has been segmented into scaffolds, tissue grafts, and other products. Tissue grafts are further categorized into allografts, autografts, xenografts, and synthetic grafts. In 2022, the scaffold segment accounted for the largest share of the tissue engineering market. Increasing research activities for the development of advanced solutions for the repair and reconstruction of damaged tissues and organs is driving the demand for scaffolds.

Based on material, the tissue engineering market has been differentiated into synthetic material and biologically derived material. The synthetic material segment holds a major market share and is expected to grow at a higher rate during the forecast period 2023-2028. This can be attributed to increasing demand for cost effective and advanced treatment solutions for tissue repair and regeneration. In addition, the increasing adoption of innovative cell therapies is promoting segment growth in the tissue engineering market.

By application, the tissue engineering market has been further categorized as cardiovascular diseases, dermatology & wound care, orthopedics & musculoskeletal disorders, dental disorders, and others. Orthopedics & musculoskeletal disorders accounted for the major market share of the tissue engineering market in 2022. The large share of this segment can be attributed to the increasing demand for high-quality advanced solutions for the treatment of bone diseases. The rising adoption of tissue engineering solutions for bone regeneration and tissue reconstruction is promoting the growth of the orthopedics & musculoskeletal disorders segment in the tissue engineering market.

Based on end users, the tissue engineering market has been categorized into hospitals, specialty centers and clinics, and ambulatory surgical centers. The ambulatory surgical centers segment is expected to grow at a higher rate during the forecast period 2023-2028. Ambulatory surgical centers are also known as same-day surgery centers. The growing adoption of advanced surgical technologies and the rising need for less time-consuming surgical processes is promoting the growth of the ambulatory surgical centers segment in the tissue engineering market.

The tissue engineering market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The rising research activities and technological advancements in the medical sector in the North American region are the major driving factors for the growth of the tissue engineering market. Additionally, increasing investments and funding for the development of innovative cell therapies for the treatment of degenerative diseases is promoting the growth of the tissue engineering market in the North America region.

Key Market Players of Tissue Engineering Industry:

Key players in the tissue engineering market include Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).

Base Editing Market in terms of revenue was estimated to be worth $270 million in 2023 and is poised to reach $549 million by 2028, growing at a CAGR of 15.2% from 2023 to 2028 according to a new report by MarketsandMarkets™.

Growing interest in gene editing technologies, including base editing, has attracted substantial funding and investment from both public and private sources. This financial support is crucial for research and development efforts, accelerating the commercialization of base editing technologies. However, ethical & safety concerns are the factors restraining market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21238371

Segments Covered	Product & Service, Type, Targeted Base, Application, and End User
Geographies Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
Report Highlights	Updated financial information / product portfolio of players
Key Market Opportunities	Increasing pipeline of gene therapy & regulatory approvals
Key Market Drivers	Rising prevalence of rare diseases

By product and service, the base editing market has been further categorized as products and services. The service segment is further categorized as gRNA design, cell line engineering, and other services. The product segment is further categorized as platform, kits & reagents, plasmids, and base editing libraries. Platform accounted for the largest share of the global base editing market in 2022. The large share of this segment can primarily be attributed to the factor that it offers integrated solutions that combine various elements required for the editing process, such as the base editor protein, guide RNA, and delivery mechanisms. This integration simplifies the workflow for researchers, as they can obtain a complete solution from a single source rather than assembling individual components.

Based on the type, the global base editing market is segmented into RNA base editing, and DNA base editing. In 2022, DNA base editing accounted for the largest share of the base editing market and the segment is expected to grow at a higher rate during the forecast period. The prominence of this segment is mainly attributed to the factor that once a base is edited in the DNA, the change is more stable over time compared to RNA-based editing. RNA is typically transient in cells, and the edits made to RNA may not persist as long as those made to DNA.

Based on end users, the base editing market has been segmented into pharmaceutical & biotechnology companies, academic research institutes, and contract research organizations. In 2022, the pharmaceutical & biotechnology segment accounted for the largest share of the base editing market. One of the major factors driving the growth of this segment is that base editing enables precise modifications at the DNA or RNA level, allowing pharmaceutical and biotech companies to develop targeted therapies for specific genetic diseases. This aligns with the industry’s shift toward precision medicine, where treatments are tailored to the individual genetic makeup of patients.

The base editing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). The availability of funding, both public and private, plays a crucial role in the development and commercialization of advanced technologies. North America has a well-established infrastructure for funding research and development initiatives, providing financial support to companies working on base editing technologies.

Key Market Players of Base Editing Industry:

Key players in the base editing market include Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), Edigene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI- Biodesign (China), KromaTiD, Inc. (US), and GenKOre. (South Korea).

Base Editing Market Recent Developments:

In May 2023, Revvity entered into a license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.
In July 2022, Beam Therapeutics entered a collaboration with Verve Therapeutics. Beam Tx granted Verve Tx a license toward an additional liver-mediated cardiovascular disease target.
In February 2022, Intellia Therapeutics acquired Rewrite Therapeutics; a private biotechnology company focused on advancing novel DNA writing technologies. This acquisition has expanded Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologies.

Interactive Patient Care Market / Interactive Patient Engagement Solutions Market is projected to reach USD 300 million by 2027 from USD 146 million in 2022, at a CAGR of 15.5% according to a new report by MarketsandMarkets™. The growth of this market is driven by the need for the adoption of improved interactive patient engagement solutions, a growing number of collaborations and partnerships between stakeholders, and favorable government regulations and initiatives to promote the adoption of these solutions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164064021

However, high infrastructural requirements and implementation costs and data security concerns are expected to restrain the growth of this Interactive Patient Care Market to a certain extent during the forecast period.

Based on product, the market is segmented into hardware and software. The hardware segment accounted for the largest share of the Interactive Patient Care Market in 2021. This segment is also projected to register the highest CAGR during the forecast period. This can be attributed to the rising development of TV-based solutions and the increased adoption of in-room televisions by hospitals.

Based on type, the market is segmented into inpatient and outpatient solutions. The inpatient solutions segment accounted for the largest share of the Interactive Patient Care Market in 2021. The large share of this segment can be attributed to the need for improved patient care and favorable government initiatives for the adoption of these solutions.

Based end users, the market is segmented into hospitals, clinics, and other end users. In 2021, the hospitals segment accounted for the largest share of the Interactive Patient Care Market / Interactive Patient Engagement Solutions Market and expected to grow at the highest CAGR during the forecast period Rising demand for IT tools to tackle the demand of hospital staff and the increasing demand for effective communication tools are driving the growth of this end-user segment.

North America accounted for the largest share of the Interactive Patient Care Market / Interactive Patient Engagement Solutions Market in 2021 and also expected to grow at the highest CAGR during the forecasted period. Favorable government initiatives, the rising prevalence of chronic diseases, and rising awareness about digital healthcare products are some of the key factors responsible for the large share and high growth rate of this market.

Prominent players in this Interactive Patient Care Market / Interactive Patient Engagement Solutions Market are:

GetWellNetwork (US), Epic Systems Corporation (US), SONIFI Health (US), Barco (Belgium), Sentrics (US), Advantech Co., Ltd. (Taiwan), Aceso Interactive Inc. (US), HealthHub Patient Engagement Solutions (Canada), Lincor, Inc. (US), eVideon (US), Remedi Complete Medical Solutions (Taiwan), i3solutions (Canada), PDi Communication Systems, Inc. (US), BEWATEC ConnectedCare GmbH (Germany), Hôpitel Inc. (Canada), Hospedia (UK), Onyx Healthcare Inc. (US), ClinicAll (US), ARBOR Technology Corp. (Taiwan), Healthcare Information, LLC (US), Oneview Healthcare (Ireland), Siemens (Germany), Vecoton (China), pCare (US), and Medix-Care GmbH (Germany).

These players are increasingly focusing on product launches, expansions, acquisitions, and partnerships to expand their product offerings in the interactive patient engagement solutions market.

Cartilage Repair / Cartilage Regeneration Market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 17.2% from 2023 to 2028 according to a new report by MarketsandMarkets. Growth in the Cartilage Repair/Cartilage Regeneration market is mainly driven by the increasing prevalence of sports and accident-related orthopedic injuries and the increasing number of osteoarthritis cases expected to offer growth opportunities for players operating in the Cartilage Repair/Cartilage Regeneration market during the forecast period. However, the High cost of cartilage repair surgeries and Unfavorable reimbursement scenarios are restricting the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37493272

Key Market Players of Cartilage Repair / Cartilage Regeneration Industry:

The Key players in the Cartilage Repair/Cartilage Regeneration market are Smith+Nephew (UK), DePuy Synthes (Johnson & Johnson) (US), Zimmer Biomet Holdings, Inc. (US), Stryker Corporation (US), Vericel Corporation (US), B. Braun Melsungen AG (US), Anika Therapeutics (US), CONMED Corporation (US), MEDIPOST (South Korea), RTI Surgical (US), Arthrex, Inc. (US), Regrow Biosciences (India), Geistlich Pharma AG (Switzerland), AlloSource (US), Orthocell Ltd, (Australia), Matricel GmbH (Germany), CartiHeal, Inc. (Israel), Regentis Biomaterials (Israel), Theracell Advanced Biotechnology (Greece), and LifeNet Health (US).

By treatment modality the Cartilage Repair/Cartilage Regeneration market is divided into Cell-based and non-cell-based categories where cell-based segment includes chondrocyte transplantation, stem cells and growth factors. The non-cell-based which are the scaffolds and cell-free composites. Cell-based including chondrocyte transplantation, growth factors, and stem cells will drive the growth of the market due to the increasing number of osteoarthritis cases.

By Application, the global Cartilage Repair/Cartilage Regeneration market is broadly segmented into hyaline cartilage and fibrocartilage. Hyaline cartilage is expected to grow highest in the upcoming years. The increasing number of hospitals and advancement in cartilage repair products will drive the growth of this application segment. Technological advancements, product developments and launches, and growing partnerships between key market players and hospitals are also supporting market growth.

By application site, the global Cartilage Repair/Cartilage Regeneration market is broadly segmented into knee, hip, ankle & foot, and other application sites (nose and shoulder). The knee is expected to grow highest in the upcoming years. The increasing number of Knee replacement procedures performed worldwide is the major factor driving the growth of this application site segment. For Instance, according to the American Orthopedic Society for Sports Medicine, over 4 million knee arthroscopy procedures are performed worldwide each year; 700,000 are conducted in the US.

Based on the region, the Cartilage Repair/Cartilage Regeneration market is segmented into North America, Europe, Asia Pacific and Rest of the world. The North American market is driven by the growing focus on growing government and private investments. For instance, In March 2020, the Government of Canada granted USD 6.9 million through the Stem Cell Network’s competitive research funding, a body that supports Canada’s most promising stem cell research. This funding is channelized to support nine translational projects and four clinical trials across Canada’s regenerative medicine market, which comprises 200 researchers and trainees at 27 Canadian research institutes in Alberta, British Columbia, Quebec, and Ontario, as well as direct partnerships with several emerging biotechnology companies.

Cartilage Repair / Cartilage Regeneration Market Dynamics:

Drivers:

Increasing number of osteoarthritis cases

Restraints:

High cost of cartilage repair surgeries

Opportunities:

Technological advancements

Challenge:

Limitations of cartilage-based stem cell products

Mass Spectrometry Market in terms of revenue was estimated to be worth $5.4 billion in 2023 and is poised to reach $7.8 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™.

Factors such as increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety, growing focus on the quality of food products, increase in crude and shale gas production, and growing government initiatives for pollution control and environmental testing are high growth prospects for the mass spectrometry market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437

Mass Spectrometry Market by Product (Instrument (Triple Quadrupole, Q-TOF, FTMS, Quadrupole, TOF), Services), Sample Preparation (LC-MS, GC-MS), Application (Omics, Clinical, Environmental), End User (Pharma, Academia, F&B) & Region – Forecasts to 2028

Mass Spectrometry Key Market Players:

The mass spectrometry business is very competitive, with both established companies and newcomers competing for the same market share. As of 2022, the key players operating in the global mass spectrometry market are SCIEX AB (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan) and Bruker Corporation (US) among others.

Based on the product, the mass spectrometry is segmented into instrument and software & services. Instruments segment to register significant growth rate over the forecast period of 2023-2028. Advantages offered by instruments, such as rapid and high-resolution testing abilities with more accurate and precise results, are increasing its adoption. Consequently, the demand for mass spectrometry devices for high throughput screening is also growing. The instrument segment is further divided into hybrid mass spectrometry, single mass spectrometry and other technologies.

Based on sample preparation technique, the mass spectrometry is segmented into GC-MS, LC-MS, ICP-MS, and others. The LC-MS segment is estimated to hold the largest market share of the mass spectrometry market during the forecast period. The large share of this segment can be attributed to its ability to identify and measure a broader range of compounds with minimal sample preparation. LC-MS can identify a broader range of compounds. LC-MS is applied in many industries such as pharmaceuticals, biopharmaceuticals, forensic, industrial, food and environmental sector. For clinical research, the analysis of drugs, vitamins and minerals in whole blood, plasma, serum and urine is conducted routinely using LCMS. It is a more sensitive instrument.

Based on application, the mass spectrometry is segmented into OMICS research, drug discovery, environmental testing, food testing, pharma-biopharma manufacturing, clinical diagnostics, applied industries, and other applications. The OMICS research segment is estimated to hold the largest market share of the mass spectrometry market during the forecast period. The large share of this segment can be attributed to the increasing application of omics technology in diagnostics & biomarker identification and the increasing R&D expenditure and government funding for proteomics are expected to drive the market for this segment.

The major end users in the mass spectrometry market are pharmaceutical companies, biotechnology companies, research labs & academic institutes, environmental testing labs, F&B industry, forensic labs, petrochemical industry and other end users. Pharmaceutical companies are expected to dominate the market during the forecast period. The availability of government and corporate funding for pharmaceutical research, growth of the pharmaceutical industry, and the presence of stringent regulatory guidelines for drug development and safety are some of the key factors driving the growth of this segment during the forecast period.

In 2023, Asia Pacific is expected to register a significant growth in the market during the forecast period. Asia Pacific comprises the China, Japan, India, South Korea, Australia, ASEAN Region, rest of APAC. Factors such as the significant funding for mass spectrometry and environmental monitoring regulations are driving the growth of the Asia Pacific mass spectrometry market.

Mass Spectrometry Market Dynamics:

Drivers:

Increasing R&D investments in the pharmaceutical and biotechnology industry

Restraints:

Premium Product Pricing

Opportunities:

Growth opportunities in emerging countries

Challenges:

Dearth of Skilled Professionals

Medical Aesthetics Market in terms of revenue was estimated to be worth $15.4 billion in 2023 and is poised to reach $25.9 billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028 according to a new report by MarketsandMarkets™.

Medical Aesthetics Market by Product (Botox, Filler, Peel, Implant, Liposuction, Microneedling, Hair Removal, Laser Resurfacing, RF, Phototherapy), Procedure (Surgical, Nonsurgical), End User (Hospital, Beauty Clinic, Spa), Region – Global Forecast to 2028

The market’s growth is significantly propelled by the rising popularity of aesthetic procedures among the elderly demographic. As people age, there is a heightened desire to maintain a youthful appearance, leading to increased demand for cosmetic treatments such as facelifts, Botox, and dermal fillers. Moreover, advancements in medical aesthetics have made these procedures safer and more accessible, further enticing older individuals. This trend reflects a broader societal shift towards embracing aging with vitality and confidence, contributing substantially to the market’s expansion.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=885

Based on the product, the global Medical Aesthetics Market is segmented into facial aesthetic products, cosmetics implants, skin aesthetic devices, body contouring devices, physician-dispensed cosmeceuticals and skin lighteners, hair removal devices, tattoo removal devices, thread lift products, physician- dispensed eyelash products and nail treatment laser devices. The facial aesthetic products segment is anticipated to register the highest growth rate over the forecast period. The facial aesthetic products segment accounted for the highest share of the Medical Aesthetics Market in 2023.

Based on procedure, the medical aesthetics market is segmented into surgical procedures – breast augmentation, rhinoplasty, facelift and body lift, other surgical procedures, non-surgical procedures – anti-aging and skin rejuvenation, tattoo and scar removal, hair removal, lipolysis, other non-surgical procedures. Non-surgical procedures segment accounted for the largest share of the market in 2022 and is also expected to grow at the highest CAGR during the forecast period.

Factors such as the Growing interest in cosmetic procedures among males of the medical aesthetics market drive the growth of the market.

Based on end user, the global Medical Aesthetics Market is segmented into clinics, hospitals, and medicals spas, beauty centers, and home care settings. The clinics, hospitals, and medicals spas segment accounted for the largest share of the market in 2023. Significant rise in the number of hospitals and rising old-age population are driving the growth of this segment.

The Asia Pacific Medical Aesthetics Market is anticipated to register the highest growth from 2023 to 2028. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC. This region is consistently witnessing a rise in the adoption of high-end equipment. Improvements in healthcare systems and government initiatives for modernizing the healthcare infrastructure are offering significant growth opportunities for the key players.

Medical Aesthetics Market Dynamics:

Drivers:

The increasing embrace of minimally invasive and non-surgical aesthetic treatments

Restraints:

Stringent regulatory compliance and safety standards in medical aesthetics

Opportunities:

Substantial prospects await market participants in developing nations

Challenge:

The presence of alternative beauty and cosmetic products

Key Market Players:

As of 2023, prominent players in the Medical Aesthetics Market are Abbvie Inc. (US), Bausch Health Companies Inc. (Canada), Johnson & Johnson (US), and among others.

Recent Developments:

In March 2023, Galderma introduced “FACE by Galderma,” an augmented reality (AR) tool that empowers both aesthetic professionals and patients to preview injectable treatment results before the actual procedure, enhancing the treatment planning process.
August 2022, AbbVie Inc. launched SkinMedica Firm & Tone Lotion for Body, the first product from the professional-grade skincare line formulated to prevent and address visible signs of the body.
March 2021, Bausch Health Companies Inc. and its Solta Medical business announced the US launch of the Clear + Brilliant Touch laser, a next-generation product that delivers a customized and more comprehensive treatment protocol by providing patients of all ages and skin types with the benefits of two wavelengths.

Enteral Feeding Devices Market in terms of revenue was estimated to be worth $3.7 billion in 2022 and is poised to reach $5.2 billion by 2027, growing at a CAGR of 6.9% from 2022 to 2027.

Surging growth in the elderly population; rising healthcare costs; rising prevalence of chronic diseases such as cancer, gastrointestinal diseases, diabetes, and neurological disorders; high number of preterm births and genetic disorders among pediatrics and neonatal populations; rising awareness towards nutritional therapies; and growing improvements in healthcare facilities across emerging countries are driving the growth of the enteral feeding devices market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183623035

The key players operating in the enteral feeding devices market include Nestlé S.A. (Switzerland), Fresenius Kabi (Germany), Cardinal Health, Inc. (US), Avanos Medical, Inc. (US), B. Braun Melsungen AG (Germany), and Becton, Dickinson and Company (US).

By type, the enteral feeding devices market is segmented into enteral feeding tubes, enteral feeding pumps, enteral syringes, administration sets, and consumables. Administration sets is expected to show fastest growth during the forecast period. The increasing focus on patient care and product safety has led to the introduction of ENFit Connectors as per the new standards to help reduce the risk of misconnections and safety issues. This, in addition to the growth in the number of patients seeking enteral nutrition across the globe, has spurred the demand for administration sets globally.

Based on age group, the enteral feeding devices market is segmented into adult patients (18 years and above) and pediatric patients (that includes neonates, infants, and children between 2-12 years of age, and adolescents between 12-16 years of age). Pediatric patients segment is expected to show fastest growth rate during the forecast period. Increasing cases of preterm births and genetic disorders among pediatric patients is driving the rapid growth in demand for providing enteral nutrition therapy in pediatric age group segment. Additionally, a growing number of pediatric patients have been diagnosed with conditions often associated with adults in the past, such as diabetes, obesity, and cancer. The increasing prevalence of such diseases among pediatric patients has further increased the demand for medications and nutritional feed delivery systems tailored for this segment.

In 2020, the oncology segment accounted for the largest share of the enteral feeding devices market, followed by gastrointestinal diseases, neurological disorders diabetes, hypermetabolism, and other applications. The oncology segment will continue to dominate the market by 2026, growing at a CAGR during the forecast period. The increase in the prevalence of various types of cancers—especially head & neck cancers, cancers of the gastrointestinal system, lung cancer, and liver cancer—is expected to play a major role in the higher adoption of enteral feeding devices used to provide clinical nutrition to cancer patients

Enteral feeding devices market by end user includes Hospitals, home care settings, and ambulatory care settings. The home care settings segment is expected to show fastest growth rate during the forecast period. Home enteral nutrition (HEN) is used in patients with a functional gastrointestinal (GI) tract and who can receive therapy outside an acute care setting. Due to the increasing pressure on hospitals to curtail the soaring healthcare costs and the COVID-19 outbreak, there has been a shift from extended hospital treatment towards treatment at home. As a result, the demand for home based nutritional care is increasing, which is expected to drive a rapid growth in the home care settings segment through 2027.

By Region, the enteral feeding devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to show the highest growth rate during the forecast period. Several factors such as rising geriatric population, increased awareness of and accessibility to advanced healthcare facilities, rising healthcare spending, growing focus of key market players on the emerging Asia Pacific countries, and rapid improvements in the health insurance sector are driving the growth of the Asia Pacific enteral feeding devices market

Enteral Feeding Devices Market Dynamics:

Drivers:

Shift from parenteral to enteral nutrition for patients
High incidence of preterm births and genetic disorders in pediatric and neonatal patients
Growing demand for enteral feeding in home care sector
Rapid growth in geriatric population and age-related chronic diseases
Increasing prevalence of dysphagia

Restraints:

Complications associated with enteral feeding devices

Opportunities:

High growth opportunities for market players in developing countries

Challenges:

Insufficient reimbursement policies for enteral nutrition therapy in developing countries
Dearth of skilled professionals and endoscopy specialists

The report “Patient Handling Equipment Market by Type (Patient Transfer Devices (Lifts , Sliding Sheets), Medical Beds (Electric, Manual), Mobility Devices (Powered Wheelchairs, Mobility Scooters), End User (Hospitals, Home-care Settings) – Global Forecast to 2027″, is projected to reach USD 14.0 billion by 2027 from USD 10.4 billion in 2022, at a CAGR of 6.2%.

The growth of this market is primarily fuelled by the growing number of obese and geriatric populations, high risk of injuries to healthcare providers during the manual handling of patients, rising number of patient admissions in hospitals, and the implementation of regulations and guidelines ensuring the safety of healthcare workers during the manual lifting. However, improper training provided to caregivers for the efficient operation of patient handling equipment is a major factor hampering the market growth.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186358368

The key players operating in the patient handling equipment market include include Arjo (Sweden), Baxter International Inc. (US), Savaria (Canada), Invacare Corporation (US), Stryker (US), Drive DeVilbiss Healthcare (US), Etac AB (Sweden), GF Health Products, Inc. (US), V. Guldmann A/S (Denmark), Joerns Healthcare LLC (US), Medline Industries, Inc. (US), Prism Medical UK Ltd. (UK), LINET (Czech Republic), Stiegelmeyer GmbH & Co. KG (Germany), Benmor Medical (UK), Malvetio Spa (Italy), EZ Way, Inc. (US), Ossenberg GmbH (Germany), Antano Group (Italy), Winncare (UK), Getinge AB (Sweden).

By type, the patient handling equipment market is segmented into medical beds, patient transfer devices, mobility devices, bathroom & toilet assist equipment, and stretchers & transport chairs. In 2021, the patient transfer devices is expected to register highest growth during the forecast period. The high share of this segment can primarily considered to the rising installation of ceiling lifts in hospitals and the rising adoption of patient lifts for bariatric patient handling.

By end users, the patient handling equipment market is segmented into home care settings, hospitals, and other end users. In 2021, the hospitals segment accounted for the largest share of the patient handling equipment market. Growth can be attributed due to the rising number of patient population, rising number of disabled people, growing number of geriatric populations, and the increasing number of injuries caused during the patient handling.

By region, patient handling equipment market is segmented into North America, Europe, Asia Pacific, Latin America and Middleeast and Africa. In 2021, Europe accounted for the largest share of the global patient handling equipment market. The large share of this market can be attributed due to the presence of large number of patient handling equipment manufacturers in Europe and the increasing number of government and non-government initiatives to adopt safe patient handling equipment. The Asia Pacific patient handling equipment market is expected to grow at the highest CAGR during the forecast period of 2022-2027. The Asia Pacific market growth is attributed to the increasing number of healthcare facilities in Asian countries.

Recent Developments:

In September 2022, Handicare offers an expanded portfolio, including the Garaventa Lift range of wheelchair platform lifts, as well as new and improved products, such as the 4000 curved stairlifts.
In May 2022, Invacare launched Birdie Evo XPLUS, an innovative patient lift solution for post-acute care settings. With its sleek and modern design, it provides innovative technology that helps maximize comfort and security when lifting or transferring a patient to or from a bed, chair or floor.
In March 2022, Stryker launched the Multi-Position MATS Mobile Air Transfer System, that prevents patients from sliding during tilt procedures and protect nurses during pre- and post-surgical lateral transfers.
In May 2021, Hill-Rom participated in the fire-side chat in the UBS Global Healthcare Virtual Conference to support its healthcare business.

Tissue Engineering Market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $8.9 billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growing demand for innovative tissue engineering solutions for the treatment of chronic diseases and for repair and regeneration of tissues and technological developments such as 3D bioprinting is promoting the growth of the tissue engineering market.

Tissue Engineering Market by Product (Scaffolds (Collagen, Stem Cell), Tissue Grafts (Allograft, Autograft, Xenograft)), Material (Biological, Synthetic), Application (Orthopedics, Dermatology, Wound Care, Cardiovascular) – Global Forecast to 2028

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34135173

Tissue Engineering Market Dynamics:

Drivers:

Growing need for regenerative medicines

Restraints:

High treatment cost

Opportunities:

Increasing technological advancements such as 3D printing and Quantum Magnetic Resonance Therapy (QMRT)

Challenge:

Cost effective traditional organ transplant techniques

Key Market Players of Tissue Engineering Industry:

Temperature Management Systems Market in terms of revenue was estimated to be worth $3.0 billion in 2023 and is poised to reach $3.9 billion by 2028, growing at a CAGR of 4.9% from 2023 to 2028 according to a new report by MarketsandMarkets™.

Temperature Management Systems Market by Product (Warming Systems (Surface, Intravascular), Cooling Systems, Application (Perioperative, Acute, Newborn Care), Medical Speciality (Cardiology, Neurology, Pediatrics, Orthopedics) – Global Forecast to 2028

Growth in the temperature management systems market is mainly driven by the increasing prevalence of chronic and infectious diseases, the rising number of surgical procedures, and the increasing number of hypothermia cases expected to offer growth opportunities for players operating in the temperature management systems market during the forecast period. However, the high cost of intravascular temperature management systems and a lack of awareness are restricting the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141546773

The Temperature Management Systems market, by product, has been segmented into patient warming systems, patient cooling systems, and accessories for patient warming/cooling systems. Patient warming systems will drive the growth of the market due to increasing number of hypothermia cases. In the US and Canada, the number of hypothermia-related deaths is estimated at 25,000 and 8,000, respectively. Preventing inadvertent perioperative hypothermia helps to reduce surgical-site infections, the length of hospital stays, and the cost per patient.

By Application, the global Temperature Management Systems market is broadly segmented into Perioperative care, acute care, newborn care, and other applications. Perioperative care is expected to grow highest in the upcoming years. The increasing number of hospital and advance medical surgical procedures will driving the growth of this application segment. Technological advancements, product developments and launches, and growing partnerships between key market players and hospitals are also supporting market growth.

By medical specialty, the global Temperature Management Systems market is broadly segmented into general surgery, cardiology, neurology, thoracic surgery, orthopedic surgery, pediatrics, and other medical specialties (such as ophthalmic, bariatric, and cosmetic surgeries). General surgery is expected to grow highest in the upcoming years. The increasing number of surgical procedures performed worldwide is the major factor driving the growth of this medical specialty segment.

Based on the region, the Temperature Management Systems market is segmented into North America, Europe, Asia Pacific and Rest of the world. The North American market is driven by the growing focus on growing government and private investments to meet the increasing demand for increasing prevalence of chronic and infectious diseases.

Temperature Management Systems Market Dynamics:

Drivers:

Increasing number of hypothermia cases

Restraints:

Lack of awareness regarding temperature management systems in developing countries

Opportunities:

Growing number of contracts and agreements between market players

Challenge:

Product recalls

Key Market Players of Temperature Management Systems Industry:

The Key players in the Temperature Management Systems market are 3M Company (US), GE Healthcare (US), Dragerwerk AG & Co. KGAA (Germany), Ecolab (US), Asahi-kasei Corporation (Japan), Becton, Dickinson and Company (US), ICU Medical (US), Gentherm Incorporated (US), Inspiration Healthcare Group PLC (UK), Medtronic PLC (Ireland), Stryker Corporation (US), The Surgical Company (Netherlands), Adroit Medical Systems (US), Attune Medical (US), Augustine Surgical, Inc (US), Belmont Medical Technologies (US), Biegler GMBH (Austria), Encompass Group, llc (US), Enthermics, INC (US), Hirtz & Co. KG (Germany), Istanbul Medikal ltd. (Istanbul), Life Recovery Systems (US), Medcare Visions (Germany), TahatAksi (Belarus) and Beijing Eternal Medical Technology Co., Ltd (China)

Recent Developments:

In June 2023, Dragerwerk AG & Co. KGAA has launched the FDA-cleared Babyroo TN300, a new open warmer that offers supportive lung protection and temperature stability from the moment of birth through discharge.
In July 2023, Asahi-kasei Corporation (Japan) signed an agreement with BrainCool, a medical device company specializing in temperature management solutions, for the exclusive distribution of the BrainCool System/IQool System and the IQool System Pads in the US and key markets in Europe. The companies are working toward expanding distribution to select markets in Asia.
In January 2022, ICU Medical completed the acquisition of Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, the combined companies create a leading infusion therapy company with estimated pro forma combined revenues of approximately USD 2.5 billion.
In July 2022, Gentherm acquired Jiangmen Dacheng Medical Equipment Co., Ltd., a manufacturer of medical materials and medical equipment, including patient temperature management solutions.